비인강악성종양에서 유도화학요법과 방사선요법을 병행치료한 결과

The Result of Combined Treatment with Induction Chemotherpy and Radiotherapy in Nasopharyngeal Cancer

  • 서장수 (영남대학교 의과대학 이비인후과학교실) ;
  • 김용대 (영남대학교 의과대학 이비인후과학교실) ;
  • 전재윤 (영남대학교 의과대학 이비인후과학교실) ;
  • 김준홍 (영남대학교 의과대학 이비인후과학교실) ;
  • 이정화 (영남대학교 의과대학 이비인후과학교실) ;
  • 신세원 (영남대학교 의과대학 치료방사선과학교실)
  • Suh Jang-Su (Department of Otorhinolaryngology Head & Neck Surgery, College of Medicine, Yeungnam University) ;
  • Kim Yong-Dae (Department of Otorhinolaryngology Head & Neck Surgery, College of Medicine, Yeungnam University) ;
  • Chun Jae-Yun (Department of Otorhinolaryngology Head & Neck Surgery, College of Medicine, Yeungnam University) ;
  • Kim Jun-Hong (Department of Otorhinolaryngology Head & Neck Surgery, College of Medicine, Yeungnam University) ;
  • Lee Jung-Hwa (Department of Otorhinolaryngology Head & Neck Surgery, College of Medicine, Yeungnam University) ;
  • Shin Sei-Won (Department of Therapeutic Radiology, College of Medicine, Yeungnam University)
  • 발행 : 1994.11.01

초록

The malignant tumor of nasopharynx occurs in china and other oriental contries as high incidence and its prognosis is relatively poor because of frequent intracranial extension and early metastasis. Traditional therapeutic modality of nasopharyngeal cancer was definite radiotherapy, but recently some cancer institute had tried combined modality with induction chemotherapy and reported it may be valuable. We report the clinical evaluation and therapeutic result about 28 nasopharyngeal cancer patients which were treated with 2 courses of induction chemotherapy(Cisplatin+5-FU) and radiotherapy. The results were as follows: 1) The 3 years and 5 years survival rate were 76% and 47% in total patients. 2) The 3 years and 5 years survival rate were 92% and 63% in T1, T2, T3 group, and 25% and 0% in T4 group. 3) The 3 year and 5 year survival rate were 100% and 60% in neck node negative group, and 60% and 40% in neck node positive group. 4) The 3 year and 5 years survival rate were 100% and 50% in stage I II group, and 71% and 44% in stage III, IV group.

키워드